Background Nanoscale drug-delivery systems (DDSs) have great promise in tumor diagnosis and treatment. Platelet membrane (PLTM) biomimetic DDSs are expected to enhance retention in vivo and escape uptake by macrophages, as well as minimizing immunogenicity, attributing to the CD47 protein in PLTM sends “ don’t eat me ” signals to macrophages. In addition, P-selectin is overexpressed on the PLTM, which would allow a PLTM-biomimetic DDS to specifically bind to the CD44 receptors upregulated on the surface of cancer cells. Results In this study, porous nanoparticles loaded with the anti-cancer drug bufalin (Bu) were prepared from a chitosan oligosaccharide (CS)-poly(lactic-co-glycolic acid) (PLGA) copolymer. These were subsequently coated with platelet membrane (PLTM) to form PLTM-CS-pPLGA/Bu NPs. The PLTM-CS-pPLGA/Bu NPs bear a particle size of ~ 192 nm, and present the same surface proteins as the PLTM. Confocal microscopy and flow cytometry results revealed a greater uptake of PLTM-CS-pPLGA/Bu NPs than uncoated CS-pPLGA/Bu NPs, as a result of the targeted binding of P-selectin on the surface of the PLTM to the CD44 receptors of H22 hepatoma cells. In vivo biodistribution studies in H22-tumor carrying mice revealed that the PLTM-CS-pPLGA NPs accumulated in the tumor, because of a combination of active targeting effect and the EPR effect. The PLTM-CS-pPLGA/Bu NPs led to more effective tumor growth inhibition over other bufalin formulations. Conclusions Platelet membrane biomimetic nanoparticles played a promising targeted treatment of cancer with low side effect. Electronic supplementary material The online version of this article (10.1186/s12951-019-0494-y) contains supplementary material, which is available to authorized users.

No abstract

MoS 2 nanosheet-capped periodic mesoporous organosilicas as a multifunctional platform for synergistic targeted chemo-photothermal therapy,

Theranostic formulations, integrating both diagnostic and therapeutic functions into a single platform, hold great potential for precision medicines. In this work, a biodegradable theranostic based on hollow mesoporous organosilica nanoparticles (HMONs) is reported and explored for ultrasound/photoacoustic dual‐modality imaging guided chemo‐photothermal therapy of cancer. The HMONs prepared are endowed with glutathione‐responsive biodegradation behavior by incorporating disulfide bonds into their framework. The nanoparticles are loaded with indocyanine green (ICG) and perfluoropentane (PFP). The former acts as a photothermal agent and the latter can generate bubbles for ultrasound imaging. A paclitaxel prodrug is developed to both serve as a redox‐sensitive gatekeeper controlling ICG release from the HMON pores and a chemotherapeutic. ICG generates mild hyperthermia upon exposure to an 808 nm laser, and this in turn leads to a liquid–gas phase transition of PFP, resulting in the generation of bubbles which can be used for ultrasound imaging. The platform is found to have excellent properties for both ultrasound and photoacoustic imaging. In addition, both in vitro and in vivo results show that the nanoparticles provide potent synergistic chemo‐photothermal therapy. The material developed in this work thus has great potential for exploitation in advanced cancer therapies.

The objective of this work was to prepare a novel filament with good biocompatibility and mechanical performance which can meet the demands of surgical sutures. Bacterial cellulose nanocrystals (BCNCs) were used to reinforce regenerated chitin (RC) fibers to form BCNC/RC filaments. Mechanical performance measurements demonstrated that the strength of the BCNC/RC filament was increased dramatically over the RC analogue. A yarn made of 30 BCNC-loaded fibers also achieved satisfactory mechanical performance, with a knot-pull tensile strength of 9.8±0.6N. Enzymatic degradation studies showed the BCNC/RC materials to have good biodegradability, the rate of which can be tuned by varying the concentration of BCNCs in the yarn. The RC and the BCNC/RC materials had no cytotoxicity and can promote cell proliferation. In vivo experiments on mice demonstrated that suturing with the BCNC/RC yarn can promote wound healing without obvious adverse effects.

Molybdenum disulfide (MoS 2) has been extensively for biomedical applications due to itsexcellent photothermal conversion ability. In this paper, we reported a nanoplatform based on folic acid (FA) targeted dual-stimuli responsive MoS 2 nanosheets (FA-BSA-PEI-LA-MoS 2-LA-PEG, FBPMP) and explore this for the treatment of FA-receptor positive human breast cancer. The nanocomposites had a uniform diameter (133 nm), and could be loaded with the anti-cancer drug doxorubicin (DOX) to a high capacity (151.4 mg/g). The release of DOX was greatly accelerated at pH 5.0 as compared to pH 7.4. In addition, it was found that drug release is enhanced under the near infrared laser (NIR) irradiation, showing that the composites can be used as dual responsive systems, with DOX release controllable through pH or NIR irradiation. MTT assays and confocal experiments showed that FBPMP nanoplatform could selectively target and kill FA-positive MDA-MB-231 cells (a human breast cancer cell line). The platform also allowed the combination of chemotherapy and photothermal therapy, which led to synergistic effects superior to either monotherapy. The functionalized MoS 2 nanoplatform developed in this work hence could be a potent system for targeted drug delivery and synergistic chemo-photothermal cancer therapy.

Noninvasive physical treatment with relatively low intensity stimulation and the development of highly efficient anticancer medical strategy are still desirable for cancer therapy. Herein a versatile, biodegradable, hollow mesoporous organosilica nanocapsule (HMONs) nanoplatform that is capped by the gemcitabine (Gem) molecule through a pH-sensitive acetal covalent bond is designed. The fabricated nanocapsule exhibits desirable small molecule release at the tumor tissues/cell sites and shows a reduced risk for drug accumulation. After loading indocyanine green (ICG), the heatshock protein 90 (Hsp 90) inhibitor, and 17AAG and modification with polyethylene glycol (NH 2 -PEG), the resulting ICG−17AAG@HMONs−Gem−PEG exhibited a precisely controlled release of ICG and 17AAG and low-temperature photothermal therapy (PTT) (∼41 °C) with excellent tumor destruction efficacy. In addition, ICG loading conferred the nanoplatform with near-infrared fluorescence imaging (FL) and photoaccoustic (PA) imaging capability. In short, this work not only presents a smart drug self-controlled nanoplatform with pH-responsive payload release and theranostic performance but also provides an outstanding low-temperature PTT strategy, which is highly valid in the inhibition of cancer cells with minimal damage to the organism. Therefore, this research provides a paradigm that has a chemodrug-gated HMONsbased theranostic nanoplatform with intrinsic biodegradability, multimodal imaging capacity, high low-temperature PTT/ chemotherapy efficacy, and reduced systemic toxicity.

In this work, an innovative boron-based multifunctional nanoplatform was developed for synergistic chemotherapy/photothermal therapy.